Boran Cheng
Overview
Explore the profile of Boran Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Cheng B, Yang X, Tong G, Wang F, Li M, et al.
Heliyon
. 2024 Feb;
10(1):e23966.
PMID: 38332868
[This corrects the article DOI: 10.1016/j.heliyon.2023.e22586.].
2.
Li C, Cheng B, Yang X, Tong G, Wang F, Li M, et al.
Heliyon
. 2023 Dec;
9(12):e22586.
PMID: 38046159
SOX8 plays an important role in several physiological processes. Its expression is negatively associated with overall survival in patients with colorectal carcinoma (CRC), suggesting SOX8 is a potential prognostic factor...
3.
Wu X, Zhou F, Cheng B, Tong G, Chen M, He L, et al.
PeerJ
. 2023 Nov;
11:e16317.
PMID: 38025711
Background: Gastric cancer (GC) is an extremely heterogeneous malignancy with a complex tumor microenvironment (TME) that contributes to unsatisfactory prognosis. Methods: The overall activity score for assessing the immune activity...
4.
Tong G, Zhu M, Chen Y, Wang S, Cheng B, Wang S, et al.
J Gastrointest Oncol
. 2022 Sep;
13(4):1668-1678.
PMID: 36092315
Background: Previous studies have shown that PD-L1-positive advanced gastric cancer (GC) patients could achieve clinical benefit after receiving immune checkpoint inhibitors (ICI) in initial or subsequent therapy. A number of...
5.
Tong G, Cheng B, Wu X, He L, Lv G, Wang S
Crit Rev Eukaryot Gene Expr
. 2022 Aug;
32(8):33-42.
PMID: 36017914
Colon cancer, as one of the common malignant tumors, has the highest morbidity and mortality. We investigated the clinical significance and possible mechanism of the circular RNA circHIPK2 in the...
6.
Li S, Wang T, Lai W, Zhang M, Cheng B, Wang S, et al.
Transl Cancer Res
. 2022 Feb;
10(12):5150-5158.
PMID: 35116365
Background: Whether sarcopenia has an impact on immune-related adverse events (irAEs) in patients with malignant neoplasms receiving immune checkpoint inhibitors (ICIs) is not consistent. This study aimed to evaluate the...
7.
Wang F, Jin F, Cheng B, Zhang Y, Zhou Q, Wang S
J Cancer Res Clin Oncol
. 2021 Aug;
148(7):1721-1735.
PMID: 34357411
Purpose: Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real...
8.
Wu X, Wu J, Tong G, Cheng B, Chen M, Yu S, et al.
Cancer Manag Res
. 2020 Aug;
12:6575-6583.
PMID: 32801895
Purpose: Dexamethasone combined with 5-hydroxytryptamine type 3 receptor antagonists (5-HT3 RA) dual regimen is the standard prophylaxis regimen for patients receiving moderately emetogenic chemotherapy (MEC). However, it has been found...
9.
Cheng B, Tong G, Wu X, Cai W, Li Z, Tong Z, et al.
Onco Targets Ther
. 2019 Oct;
12:7887-7896.
PMID: 31576146
Background: Advanced gastric cancer (aGC) has a high global incidence and a high mortality rate and because of its high malignancy and heterogeneity, the existing methods for prognosis are limited,...
10.
Tong G, Cheng B, Li J, Wu X, Nong Q, He L, et al.
Cancer Med
. 2019 Sep;
8(16):7044-7054.
PMID: 31557409
Background: Immunotherapy and its mechanisms are being studied in a wide variety of cancers. Programmed cell death ligand 1 (PDL1) is associated with immune evasion in numerous tumor types. Here,...